All News

lab.test.genetics.lavender.pcr

HLA-B27 Testing in Practice

Jack Cush, MD

A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along with other serologic tests. Optimal use of HLA-B27 testing has yet to be defined.

Read Article
back, LBP, spine, AS

Imaging in Axial Spondyloarthritis

Adela Castro, MD

The diagnosis of axial spondyloarthritis (axSpA) is clinical, however, there are still unmet needs, particularly in the diagnosis of early disease and evaluation of disease activity and progression. As imaging technology continues to evolve, its role in axSpA management is expected to expand, offering more precise, individualized care. Here are two studies presented at EULAR 2025.

Read Article
SI AS SpA ACR

Remission in Axial Spondyloarthritis Unrelated to Gut Inflammation

MedPage Today

Most patients with early, active axial spondyloarthritis (axSpA) who quickly received a tumor necrosis factor (TNF) inhibitor experienced remission, and it didn't matter whether or not they had intestinal inflammation at baseline, a small single-arm study found.

Read Article
smartphone

Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia

Antoni Chan, MD, PhD

The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence and digital health technologies. At #EULAR2025, the Bechterew-App Trial (LB0002) presented important new data on Axia, a novel AI-powered digital therapeutic developed for axSpA.

Read Article
EULAR 2025 – SpA Panel Discussion Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes. https://t.co/AcwtseWBi0 https://t.co/MzEN0VtLx6

Links:

Dr. John Cush RheumNow ( View Tweet)
Expanding the IL-17 Therapeutic Landscape IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. https://t.co/Q7Thp1HJAL
Dr. John Cush RheumNow ( View Tweet)
Putting IL17i into ‘focus’ for SpA-associated uveitis The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than https://t.co/AUEct0FxmU
Dr. John Cush RheumNow ( View Tweet)
Difficult to Treat Axial Spondyloarthritis Drs. Antoni Chan and Martina Magrey discuss abstract POS0117 presented at the 2025 EULAR meeting in Barcelona. https://t.co/isv05fzV1d https://t.co/Ji24s9qSZF

Links:

Dr. John Cush RheumNow ( View Tweet)
Lessons on Uveitis and AxSpA Dr. Adela Castro reporting from the 2025 EULAR meeting in Barcelona https://t.co/G0lDGDhpTh https://t.co/UWBSgTLyQm

Links:

Dr. John Cush RheumNow ( View Tweet)
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence (AI) and digital health technologies. Traditionally, treatment has centered around https://t.co/5CCpZqkm7K
Dr. John Cush RheumNow ( View Tweet)
Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain https://t.co/xpzeV0oZOr https://t.co/mEYnAFsYQI

Links:

Dr. John Cush RheumNow ( View Tweet)
⌛️ Diagnostic delay in #SpA: Better with time? 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay decreased over time 🔹️Same trends across world regions & across Human Development Index categories POS0908 #EULAR2025 @RheumNow https://t.co/Y9gxQDV9KJ

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Impact of TNFi on efficacy of Vunakizumab in AS. -Post hoc analysis of Vunakizumab (humanized monoclonal IgG1/k antibody targeting IL-17A) trial on AS pts. -440 total pts, 163 had prior TNFi exposure - At week 16, no significant differences in ASAS20 b/w TNFi exposed pts https://t.co/O9PFOuLa5l

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Sacroiliac joint involvement in #Psoriatic_arthritis 🔹️681 patients 🔹️Age 45 🔹️31% MRI-positive sacroiliitis 🔹️29% radiographic sacroiliitis 🔹️AxPsS associated with: peripheral arthritis, dactylitis, nail psoriasis POS0297 #EULAR2025 @RheumNow https://t.co/gKANc6mNZB

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Data from COAST-V study (post hoc) 🔹️Ixekizumab in #axSpA 🔹️Efficacy stratified by CRP level 🔹️Better treatment response in the elevated compared to the normal CRP group OP0699 #EULAR2025 @RheumNow https://t.co/1mVoly3Gws

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Is there an association btwn ⬆️ CRP & cardiovascular dysfunction in #axSpA? 🔹️245 pts 🔹️CRP recorded for past 5y 🔹️sustained high CRP in 40% 🔹️associated with ⬆️ cardiovascular risk factors, ⬇️endothelial function & subclin atheroslerosis POS0714 #EULAR2025 @RheumNow https://t.co/jAlj3sr95H

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
RCT of a digital intervention in RMDs? It was long awaited, and all the lights are green🟢! German national Bechterew-App RCT of App based intervention AXIA, control group was standard of care 200pts 12wks ASAS20 response 51% vs. 9% ASAS40 response rate 23% vs. 3% BASDAI:

Aurelie Najm AurelieRheumo ( View Tweet)

67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them. ✅ Only 13% linked SLE control to CVD risk 🚫 0% picked correct BP/statin use in RA/AS/PsA Barriers? Time, knowledge, and local guideline gaps. POS0410-HPR @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT. ASAS20: 51% vs 9%; ASAS40: 23% vs 3%. Promising app-based intervention comprising individualised exercise, pt education & disease Mx. @RheumNow #EULAR2025 #LB0002

Mrinalini Dey DrMiniDey ( View Tweet)

#EULAR2025 Abstr#LB0002 Crossover RCT of use of AXIA - a novel app-based intervention showed improvement in disease activity, functionality & quality of life in pople with Axial #SpA vs usual care. Available in Austria currently - awaiting rollout and in other languages @RheumNow https://t.co/nV4QifyikL

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×